nervous system disorder
|
0.300 |
Biomarker
|
group |
CTD_human |
A 3-dimensional human embryonic stem cell (hESC)-derived model to detect developmental neurotoxicity of nanoparticles.
|
23203475 |
2013 |
Brain Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres.
|
21127729 |
2010 |
Malignant neoplasm of brain
|
0.300 |
Biomarker
|
disease |
CTD_human |
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres.
|
21127729 |
2010 |
Benign neoplasm of brain, unspecified
|
0.300 |
Biomarker
|
disease |
CTD_human |
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres.
|
21127729 |
2010 |
Brain Tumor, Primary
|
0.300 |
Biomarker
|
disease |
CTD_human |
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres.
|
21127729 |
2010 |
Recurrent Brain Neoplasm
|
0.300 |
Biomarker
|
disease |
CTD_human |
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres.
|
21127729 |
2010 |
Primary malignant neoplasm of brain
|
0.300 |
Biomarker
|
disease |
CTD_human |
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres.
|
21127729 |
2010 |
Neoplasms, Intracranial
|
0.300 |
Biomarker
|
group |
CTD_human |
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres.
|
21127729 |
2010 |
Hyperhomocysteinemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
These findings confirm that hyperhomocysteinemia induces injury in olfactory bulb neurons by downregulating Hes1 and Hes5 expression.
|
29557377 |
2018 |
Hyperhomocysteinemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
These results suggest that HHcy-enhanced brain damage is associated with increased autophagy and neuronal apoptosis in Apo E<sup>-/-</sup> mice, in which downregulation of hes1 and hes5 is involved.
|
29171783 |
2017 |
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Multiple myeloma cell growth relies on intrinsic aggressiveness, due to a high karyotypic instability, or on the support from bone marrow (BM) niche.We and other groups have provided evidences that Notch signaling is related to tumor cell growth, pharmacological resistance, localization/recirculation in the BM and bone disease.This study indicates that high gene expression levels of Notch signaling members (JAG1, NOTCH2, HES5 and HES6) correlate with malignant progression or high-risk disease, and Notch signaling may participate in myeloma progression by increasing the BM levels of interleukin-6 (IL-6), a major player in myeloma cell growth and survival.
|
27463014 |
2016 |
Neuroblastoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
The HES2 and HES5 gene promoters were found to be heavily methylated in most neuroblastoma lines, and HES gene expression could be induced through treatment with decitabine.
|
21744479 |
2012 |
Central neuroblastoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
The HES2 and HES5 gene promoters were found to be heavily methylated in most neuroblastoma lines, and HES gene expression could be induced through treatment with decitabine.
|
21744479 |
2012 |
Childhood Neuroblastoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
The HES2 and HES5 gene promoters were found to be heavily methylated in most neuroblastoma lines, and HES gene expression could be induced through treatment with decitabine.
|
21744479 |
2012 |
Neuroblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
However, in nonserotonergic cells that express 5-HT1A receptors (septal SN48, neuroblastoma SKN-SH, and neuroblastoma/glioma NG108-15 cells), Deaf-1 enhanced 5-HT1A promoter activity at the C(-1019)-allele but not the G-allele, whereas Hes5 repressed in all cell types.
|
16467535 |
2006 |
Mucoepidermoid Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Analyses of potential downstream targets of the fusion revealed differential expression of the cAMP/CREB (FLT1 and NR4A2) and Notch (HES1 and HES5) target genes in fusion-positive and fusion-negative MECs.
|
16444749 |
2006 |
Central neuroblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
However, in nonserotonergic cells that express 5-HT1A receptors (septal SN48, neuroblastoma SKN-SH, and neuroblastoma/glioma NG108-15 cells), Deaf-1 enhanced 5-HT1A promoter activity at the C(-1019)-allele but not the G-allele, whereas Hes5 repressed in all cell types.
|
16467535 |
2006 |
Childhood Neuroblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
However, in nonserotonergic cells that express 5-HT1A receptors (septal SN48, neuroblastoma SKN-SH, and neuroblastoma/glioma NG108-15 cells), Deaf-1 enhanced 5-HT1A promoter activity at the C(-1019)-allele but not the G-allele, whereas Hes5 repressed in all cell types.
|
16467535 |
2006 |
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Analyses of the Notch target genes HES5 and MASH1 in MEC tumors with and without the WAMTP1-MAML2 fusion revealed upregulation of HES5 and downregulation of MASH1 in fusion positive MECs compared to normal salivary gland tissue and MECs lacking the fusion.
|
14720503 |
2004 |
Mucoepidermoid Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Analyses of the Notch target genes HES5 and MASH1 in MEC tumors with and without the WAMTP1-MAML2 fusion revealed upregulation of HES5 and downregulation of MASH1 in fusion positive MECs compared to normal salivary gland tissue and MECs lacking the fusion.
|
14720503 |
2004 |
Bulbo-Spinal Atrophy, X-Linked
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, Hes5 over-expression rescued the SBMA cells possibly by inducing Smad2 phosphorylation.
|
30940675 |
2019 |
Cone-Rod Dystrophy 2
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we have demonstrated that spinal cord injury enhanced oligodendrocyte precursor cell number and decreased mRNA expression of transcriptional inhibitors (Id2, Id4, hes5).
|
30527678 |
2019 |
Arteriopathic disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Treatment with GTPs upregulated the levels of Jagged1, Notch1, Hes5, p-STAT3, and MnSOD2, and downregulated xanthine oxidase (XO) expression in rats with preglomerular arteriopathy.
|
30416668 |
2018 |
Temporomandibular joint osteoarthritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The mRNA expressions of Notch1, Jagged1 and Hes5 were significantly increased in Control-TMJOA group compared with Control-Sham group.
|
29779621 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, out data have delineated that HES5 might contribute to the proliferation of NSCLC by STAT3 signaling.
|
27878283 |
2017 |